CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-12 | Alam Kamran CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +231,000 | 231,000 | ||
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 | +111,324 | $0.70 | $78K | 1,117,763 |
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 | +88,676 | $1.71 | $152K | 1,206,439 |
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 | −200,000 | $4.71 | $942K | 1,006,439 |
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Grant or award 10b5-1 | +427,000 | 1,433,439 | ||
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −111,324 | 111,359 | ||
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −88,676 | 474,941 | ||
| 2026-01-12 | Nagendran Sukumar President and Head of R&D | Grant or award · Employee Stock Option (right to buy) 10b5-1 | +274,000 | 274,000 | ||
| 2026-01-12 | Nolan Sean P. Chief Executive Officer | Grant or award | +1,008,000 | 3,086,358 | ||
| 2026-01-12 | Nolan Sean P. Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +648,000 | 648,000 | ||
| 2025-12-01 | Nagendran Sukumar President and Head of R&D | Option exercise | +260,047 | $1.71 | $445K | 1,266,486 |
| 2025-12-01 | Nagendran Sukumar President and Head of R&D | Sale | −260,047 | $4.51 | $1.2M | 1,006,439 |
| 2025-12-01 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) | −260,047 | 563,617 | ||
| 2025-11-28 | Nagendran Sukumar President and Head of R&D | Option exercise | +70,172 | $0.70 | $49K | 1,076,611 |
| 2025-11-28 | Nagendran Sukumar President and Head of R&D | Option exercise | +39,953 | $1.71 | $68K | 1,116,564 |
| 2025-11-28 | Nagendran Sukumar President and Head of R&D | Sale | −110,125 | $4.75 | $523K | 1,006,439 |
| 2025-11-28 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) | −70,172 | 222,683 | ||
| 2025-11-28 | Nagendran Sukumar President and Head of R&D | Option exercise · Employee Stock Option (right to buy) | −39,953 | 823,664 | ||
| 2025-09-10 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 | +41,150 | $0.70 | $29K | 1,206,439 |
| 2025-09-10 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 | −200,000 | $3.23 | $646K | 1,006,439 |
Page 2 of 9 · 173 trades